Market Overview

Tekmira Up 4% On Positive Ebola-Related Drug Study

Related TKMR
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
UPDATE: Dicerna Announces License Agreement With Tekmira
Making Money With Charles Payne: 10/24/14 (Fox Business)

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising results in animal studies directed at treating Ebola virus disease.

A peer-reviewed study published Wednesday found that Tekmira's lipid nanoparticle provided "complete protection" in monkeys against Marburg virus infection, the symptoms of which are indistinguishable from Ebola.

The drug appeared effective even when administered up to three days following exposure to the virus, which is closely related to Ebola, the company said.

Related Link: Time To Take Another Look At Tekmira

Results in the journal Science Translational Medicine, were trumpeted in a company press release at 2 p.m. Wednesday and later reported, including in the print edition of Thursday's New York Times.

Tekmira's similar development drug, called TKM-Ebola, got a boost August 7 when regulators modified a clinical hold on the drug to a modified hold, potentially clearing the way for human trials.

Regulators halted a Phase I study of TKM-Ebola on July 3 over safety concerns.

Tekmira traded recently at $18.51, up 4.4 percent.

Posted-In: News Health Care FDA Hot Intraday Update General

 

Related Articles (TKMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters